Diethylamino-curcumin mimic with trizolyl benzene enhances TRAIL-mediated cell death on human glioblastoma cells

Backgrounds Glioblastoma multiforme is one of the most aggressive human malignant brain tumors. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is known as the death ligand, which induces preferential apoptosis of transformed cancer cells. In this study, we demonstrated that the newl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular & cellular toxicology 2018, 14(2), , pp.241-245
Hauptverfasser: Ahn, Yongchel, Lee, Seokjoon, Park, Cheon-Soo, Jang, Hyuk Jai, Lee, Ji Hwan, Park, Byong-Gon, Park, Yoon-Sun, Shin, Woon-Seob, Kwon, Daeho
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Backgrounds Glioblastoma multiforme is one of the most aggressive human malignant brain tumors. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is known as the death ligand, which induces preferential apoptosis of transformed cancer cells. In this study, we demonstrated that the newly synthesized diethylamino-curcumin mimic with trizolyl benzene (YM-4) enhances cytotoxicity in combination with TRAIL in human glioblastoma cells. Methods We synthesized diethylamino-curcumin mimic with trizolyl benzene (YM-4) and investigated possible apoptotic cell signaling by co-treatment with YM-4 and TRAIL on human glioblastoma cells. Results Caspase-8, 9, and 3 and poly (ADP-ribose) polymerase were more efficiently cleaved with cotreatment of YM-4 and TRAIL than treatment with each alone in human glioblastoma cells. Co-treatment with YM-4 and TRAIL significantly increased the expression of Bax and Smac/Diablo and also inhibited the expression of the X-linked inhibitor of apoptosis protein and Survivin in human glioblastoma cells. Conclusion These results demonstrated that YM-4 can be an anticancer candidate that can be effective on human glioblastoma cells in combination with TRAIL.
ISSN:1738-642X
2092-8467
DOI:10.1007/s13273-018-0026-0